A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis

Brief summary (registry, in English)

The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).

What you commit to

• Study type: Interventional · Phase 3
• Participants enrolled: 418
• From 13 Sept 2022 to the primary completion date, 2 Apr 2024
• 210 sites in 25 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (210)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Related publications

• Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial.Lancet Gastroenterol Hepatol · 2026 · PMID 41544637